NCT00682448View on ClinicalTrials.gov

Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Metabolic Complications
Interventions
DRUG

Metformin

Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.

DRUG

Placebo

Drug: Placebo. Subjects will remain on placebo for 6 months.

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Rush University Medical Center

OTHER

NCT00682448 - Metformin for the Prevention of the Metabolic Side-effects of Zyprexa | Biotech Hunter | Biotech Hunter